Enochian Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.34
- Today's High:
- $1.62
- Open Price:
- $1.43
- 52W Low:
- $0.724
- 52W High:
- $3.83
- Prev. Close:
- $1.48
- Volume:
- 919595
Company Statistics
- Market Cap.:
- $42.56 million
- Book Value:
- 1.14
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -9.94%
- Return on Equity TTM:
- -93.88%
Company Profile
Enochian Biosciences Inc had its IPO on 2015-02-02 under the ticker symbol ENOB.
The company operates in the Healthcare sector and Biotechnology industry. Enochian Biosciences Inc has a staff strength of 22 employees.
Stock update
Shares of Enochian Biosciences Inc opened at $1.43 at the start of the last trading session i.e. 2023-08-13.
The stocks traded within a range of $1.34 - $1.62, and closed at $1.56.
This is a +5.41% increase from the previous day's closing price.
A total volume of 919,595 shares were traded at the close of the day’s session.
In the last one week, shares of Enochian Biosciences Inc have increased by +122.86%.
Enochian Biosciences Inc's Key Ratios
Enochian Biosciences Inc has a market cap of $42.56 million, indicating a price to book ratio of 0.4499 and a price to sales ratio of 0.
In the last 12-months Enochian Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-20464270. The EBITDA ratio measures Enochian Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Enochian Biosciences Inc’s operating margin was 0% while its return on assets stood at -9.94% with a return of equity of -93.88%.
In Q1, Enochian Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Enochian Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.84 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enochian Biosciences Inc’s profitability.
Enochian Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.7268. Its price to sales ratio in the trailing 12-months stood at 0.
Enochian Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $78.73 million
- Total Liabilities
- $11.77 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Enochian Biosciences Inc ended 2024 with $78.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $78.73 million while shareholder equity stood at $66.13 million.
Enochian Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $11.77 million in other current liabilities, 5800.00 in common stock, $-220831001.00 in retained earnings and $11.64 million in goodwill. Its cash balance stood at $2.95 million and cash and short-term investments were $2.95 million. The company’s total short-term debt was $6,207,233 while long-term debt stood at $0.
Enochian Biosciences Inc’s total current assets stands at $3.93 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $4.47 million and inventory worth $0.
In 2024, Enochian Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Enochian Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.56
- 52-Week High
- $3.83
- 52-Week Low
- $0.724
- Analyst Target Price
- $
Enochian Biosciences Inc stock is currently trading at $1.56 per share. It touched a 52-week high of $3.83 and a 52-week low of $3.83. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.67 and 200-day moving average was $1.11 The short ratio stood at 26.81 indicating a short percent outstanding of 0%.
Around 5805.9% of the company’s stock are held by insiders while 655.3% are held by institutions.
Frequently Asked Questions About Enochian Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company’s product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.